Argutus Medical enters partnership with CeeTox Inc.
Posted Wednesday, June 24, 2009
KALAMAZOO, Michigan – June 24, 2009
Argutus Medical Ltd. of Dublin, Ireland has named CeeTox Inc., Kalamazoo, MI, a preferred reference laboratory for Argutus’ novel acute kidney injury (AKI) biomarker panel – the AKI Test®. In addition, CeeTox will also run Argutus’ assays for kidney toxicity of the proximal tubule, distal tubule collecting duct and loop of Henle.
“Our AKI Test® panel of specific kidney injury assays lets pharmaceutical researchers and clinical trial directors know sooner whether drugs are causing renal damage. The AKI Test is composed of biomarker tests for proximal tubule, distal tubule and collecting duct injury, and thus identifies where in the kidney damage is occuring with much greater sensitivity and specificity than the traditional tests of creatinine or BUN,” says Joe Keenan, Head of Sales & Marketing at Argutus.
“By providing an earlier method of identifying potential adverse reactions, clinicians and researchers can modify their studies and treatment protocols, minimizing risk to patients and study participants, saving both time and money.”
CeeTox has worked with kits from Argutus, formerly Biotrin, since its inception six years ago. According to Dr. James McKim, Founder and CSO of CeeTox, “Argutus kits are easy to use, cost effective and reliable. They are an integral part of our CTOX Panel offering. We are pleased to be named a preferred reference laboratory by Argutus.”
CeeTox is a leader in in vitro toxicity testing, with screens for Acute Toxicity, Drug-Drug Interaction, Cardiotox, Skin Irritation, Skin Corrosion, Percutaneous Absorption, Phototoxicity, Ocular Corrosion and Irritation, Skin Sensitization, Endocrine Disruption, and In Vitro Acute OralTox LD50.
For more information about the AKI Test® or site specific biomarkers, contact Joe Keenan, Head of Sales & Marketing at Argutus Medical (Joe.Keenan@argutusmed.com – ph. +353 1 670 8576 Ext. 201) or Syed Ahmed Mustafa, Director of Sales & Marketing at CeeTox, Inc. (Smustafa@ceetox.com – ph. +1 269-532-3800).